Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 [carisbamate] as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures.

Trial Profile

A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 [carisbamate] as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors SK Life Science
  • Most Recent Events

    • 01 Aug 2012 SK Life Science added as trial association and lead trial centre as reported by ClinicalTrials.gov (Parent trial: NCT00697762).
    • 17 Mar 2011 Actual end date is Apr 2009 for extension trial ClinicalTrials.gov.
    • 17 Mar 2011 Actual initiation date is Mar 2008 according to extension trial ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top